# Phase 3 dermatitis trials recruiting: 29 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 29 trials in phase 3 for dermatitis that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 3 dermatitis trials: 29 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-3/dermatitis

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 29
- Recruiting or not yet: 29
- Read on: November 19, 2026

## Trials

The 25 newest of 29, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 5, 2026 | NCT07919899 | Pharmacokinetics, Immunogenicity and Safety of Subcutaneous Dupilumab and Berahyaluronidase Alfa (ALT-B4) Coformulation | Sanofi | Phase 3 | Not yet recruiting | Dermatitis Atopic | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919899) |
| November 4, 2026 | NCT07916480 | Roflumilast Cream 0.3% for Moderate to Severe Atopic Dermatitis | Arcutis Biotherapeutics, Inc. | Phase 3 | Recruiting | Atopic Dermatitis, Atopic Dermatitis (AD), Atopic Dermatitis (Eczema) | 415 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07916480) |
| October 14, 2026 | NCT07873801 | A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis | Almirall, S.A. | Phase 3 | Not yet recruiting | Atopic Dermatitis | 230 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07873801) |
| September 16, 2026 | NCT07823595 | Abrocitinib Treatment of Atopic Dermatitis in Children 2 to Less Than 6 Years of Age | Pfizer | Phase 3 | Not yet recruiting | Atopic Dermatitis | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07823595) |
| August 24, 2026 | NCT07783425 | A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema | Pfizer | Phase 3 | Recruiting | Atopic Dermatitis | 1,375 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07783425) |
| August 17, 2026 | NCT07767253 | Evaluation of 611 in Chinese Children With Moderate to Severe Atopic Dermatitis(AD) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Phase 3 | Recruiting | Dermatitis, Atopic | 246 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07767253) |
| August 14, 2026 | NCT07765888 | A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema | Pfizer | Phase 3 | Recruiting | Atopic Dermatitis | 375 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07765888) |
| August 13, 2026 | NCT07762833 | Randomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Subjects With Moderate-to-severe Atopic Dermatitis | Galderma R&D | Phase 3 | Recruiting | Atopic Dermatitis | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07762833) |
| August 10, 2026 | NCT07754786 | A Study to Evaluate the Equivalence of IBI3027 and Dupilumab Injection in Participants With Moderate to Severe Atopic Dermatitis | Innovent Biologics (Suzhou) Co. Ltd. | Phase 3 | Recruiting | Atopic Dermatitis | 520 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07754786) |
| July 6, 2026 | NCT07683806 | Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrheic Dermatitis | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Seborrheic Dermatitis | 309 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07683806) |
| May 18, 2026 | NCT07592585 | Phase III Clinical Study of VC005 in Adult and Adolescents With Mild to Moderate Atopic Dermatitis | Jiangsu vcare pharmaceutical technology co., LTD | Phase 3 | Recruiting | Atopic Dermatitis | 360 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07592585) |
| April 21, 2026 | NCT07542483 | A Study of Lebrikizumab in Adults With Nummular Eczema | Almirall, S.A. | Phase 3 | Recruiting | Nummular Eczema | 270 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07542483) |
| April 20, 2026 | NCT07540442 | A Phase III Study of MG-K10 in Adolescents With Moderate-to-Severe Atopic Dermatitis | Shanghai Mabgeek Biotech.Co.Ltd | Phase 3 | Not yet recruiting | Dermatitis, Atopic | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07540442) |
| March 18, 2026 | NCT07479615 | A Study to Evaluate the Efficacy and Safety of MG-K10 in Participants Who Have Atopic Dermatitis | Shanghai Mabgeek Biotech.Co.Ltd | Phase 3 | Not yet recruiting | Atopic Dermatitis, Atopic Eczema | 498 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07479615) |
| February 4, 2026 | NCT07386743 | A Phase III Study of GS101 Injection to Dupixent® | Jiangsu Genscend Biopharmaceutical Co., Ltd | Phase 3 | Recruiting | Atopic Dermatitis (AD) | 572 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07386743) |
| January 30, 2026 | NCT07377838 | Study of ADSTEM Injection for Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis | EHL Bio Co., Ltd. | Phase 3 | Recruiting | Atopic Dermatitis | 286 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07377838) |
| September 22, 2025 | NCT07184645 | A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atopic Dermatitis | Otsuka Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Atopic Dermatitis (AD) | 198 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07184645) |
| September 15, 2025 | NCT07173478 | A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic Dermatitis | Otsuka Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Atopic Dermatitis (AD) | 156 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07173478) |
| September 9, 2025 | NCT07162896 | Crisaborole 2% Versus Tacrolimus 0.1% in Children With Mild to Moderate Atopic Dermatitis | Shalamar Institute of Health Sciences | Phase 3 | Not yet recruiting | Atopic Dermatitis, Atopic Dermatitis (AD) | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07162896) |
| August 6, 2025 | NCT07106372 | A Study of Stapokibatrt in Children Subjects With Atopic Dermatitis | Keymed Biosciences Co.Ltd | Phase 3 | Not yet recruiting | Atopic Dermatitis | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07106372) |
| June 27, 2025 | NCT07042126 | Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Phase 3 | Recruiting | Dermatitis, Atopic | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07042126) |
| May 4, 2025 | NCT06956196 | Study of Stapokibatrt in Children Subjects With Atopic Dermatitis | Keymed Biosciences Co.Ltd | Phase 3 | Not yet recruiting | Atopic Dermatitis | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06956196) |
| March 19, 2025 | NCT06884891 | A Phase Ⅲ Comparative Study of QL2108 to Dupixent® | Qilu Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Atopic Dermatitis | 520 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06884891) |
| March 17, 2025 | NCT06880276 | Efficacy and Safety Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis | Qilu Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Atopic Dermatitis | 360 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06880276) |
| February 4, 2025 | NCT06807281 | A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema | Pfizer | Phase 3 | Recruiting | Atopic Dermatitis | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06807281) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 4 |
| [Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.](https://specstream.ai/data/clinical-trials/company/sunshine-guojian-pharmaceutical-shanghai-co-ltd) | 2 |
| [Otsuka Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/otsuka-pharmaceutical-co-ltd) | 2 |
| [Almirall, S.A.](https://specstream.ai/data/clinical-trials/company/almirall-s-a) | 2 |
| [Keymed Biosciences Co.Ltd](https://specstream.ai/data/clinical-trials/company/keymed-biosciences-co-ltd) | 2 |
| Shanghai Mabgeek Biotech.Co.Ltd | 2 |
| [Qilu Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/qilu-pharmaceutical-co-ltd) | 2 |
| Jiangsu Genscend Biopharmaceutical Co., Ltd | 1 |
| EHL Bio Co., Ltd. | 1 |
| [Arcutis Biotherapeutics, Inc.](https://specstream.ai/data/clinical-trials/company/arcutis-biotherapeutics-inc) | 1 |
| [LEO Pharma](https://specstream.ai/data/clinical-trials/company/leo-pharma) | 1 |
| [Innovent Biologics (Suzhou) Co. Ltd.](https://specstream.ai/data/clinical-trials/company/innovent-biologics-suzhou-co-ltd) | 1 |
| [Jiangsu vcare pharmaceutical technology co., LTD](https://specstream.ai/data/clinical-trials/company/jiangsu-vcare-pharmaceutical-technology-co-ltd) | 1 |
| [Sanofi](https://specstream.ai/data/clinical-trials/company/sanofi) | 1 |
| [Akeso](https://specstream.ai/data/clinical-trials/company/akeso) | 1 |
| Prime Gene Therapeutics Co., Ltd. | 1 |
| [Beijing InnoCare Pharma Tech Co., Ltd.](https://specstream.ai/data/clinical-trials/company/beijing-innocare-pharma-tech-co-ltd) | 1 |
| [Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/hangzhou-zhongmei-huadong-pharmaceutical-co-ltd) | 1 |
| [Galderma R&D](https://specstream.ai/data/clinical-trials/company/galderma-r-and-d) | 1 |
| Shalamar Institute of Health Sciences | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 15 |
| Japan | 5 |
| United States | 5 |
| Canada | 3 |
| South Korea | 2 |
| Germany | 2 |
| Poland | 2 |
| Spain | 2 |
| Belgium | 1 |
| Croatia | 1 |
| Ireland | 1 |
| Italy | 1 |
| Netherlands | 1 |
| Romania | 1 |
| United Kingdom | 1 |
| Hungary | 1 |
| Mexico | 1 |
| Pakistan | 1 |
| Taiwan | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Driving schools in the United States](https://specstream.ai/data/businesses/driving-schools/united-states)
- [Abrasives suppliers in the United States](https://specstream.ai/data/businesses/abrasives-suppliers/united-states)
- [Personal injury law firms in the United States](https://specstream.ai/data/businesses/personal-injury-law-firms/united-states)
- [Furniture rental companies in the United States](https://specstream.ai/data/businesses/furniture-rental-companies/united-states)
- [Bank equipment companies in the United States](https://specstream.ai/data/businesses/bank-equipment-companies/united-states)
- [Screen printers in the United States](https://specstream.ai/data/businesses/screen-printers/united-states)
